Return to homepagePandemic Pact

Development of splenic marginal B cell-targeted coronavirus vaccine using PEG-modified exosomes

Grant number: 20F20411

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2023

  • Known Financial Commitments (USD)

    $22,080

  • Funder

    KAKENHI

  • Principal Investigator

    N/A

  • Research Location

    Japan

  • Lead Research Institution

    The University of Tokushima

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Using PEGylated antigen-expressing extracellular vesicles to accomplish splenic B cell-targeted antigen delivery for induction of antibodies against SARS-CoV-2 spike protein.